SCHEMBL25834774

SCHEMBL25834774

CC(C)C(=O)CCCCCCCCCCCCCCCO

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.50
FFAR1 O14842 1/20 0.50
FFAR4 Q5NUL3 1/20 0.50
KDM4E B2RXH2 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CES2 O00748 1/20 0.41
MEN1 O00255 1/20 0.39
FAAH O00519 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
LMNA P02545 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2528854 1.00 GPR84 (0.50) GPR84FFAR1FFAR4KDM4ESMN1; SMN2
SCHEMBL7582371 1.00 GPR84 (0.50) GPR84FFAR1FFAR4KDM4ESMN1; SMN2
SCHEMBL18269439 1.00 GPR84 (0.50) GPR84FFAR1FFAR4KDM4ESMN1; SMN2
SCHEMBL25834870 1.00 GPR84 (0.50) GPR84FFAR1FFAR4KDM4ESMN1; SMN2
SCHEMBL9947521 1.00 GPR84 (0.50) GPR84FFAR1FFAR4KDM4ESMN1; SMN2
SCHEMBL2528919 0.97 GPR84 (0.46) GPR84FFAR1FFAR4KDM4ESMN1; SMN2
SCHEMBL2532886 0.90
SCHEMBL9973392 0.89 CES2 (0.48) CES2MEN1FAAHMAPK1KMT2A
SCHEMBL9973396 0.89 CES2 (0.48) CES2MEN1FAAHMAPK1KMT2A
SCHEMBL18751717 0.89 CES2 (0.48) CES2MEN1FAAHMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912997-B2 RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use Arrowhead Pharmaceuticals, Inc. (US) 2024-02-27 US disclosed
US-20240026363-A1 RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT 2024-01-25 US disclosed
US-20240026363-A1 RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT 2024-01-25 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912997-B2 RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use SOD1, SOD3, SMN1; SMN2 GPR84 4743/4885FFAR1 4668/4885FFAR4 4865/4885
US-20240026363-A1 RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use SOD1, SOD3, SMN1; SMN2 GPR84 4744/4885FFAR1 4674/4885FFAR4 4865/4885
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 GPR84 2887/4885FFAR1 1075/4885FFAR4 1552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.